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HIV-1 viral protein U (Vpu) facilitates virus particle release. To determine whether Gag is sufficient for generation of a
target for Vpu-mediated particle release, we expressed HIV-1 Gag protein in the absence of the other viral genes. The
resulting particles were still Vpu responsive. Mutational analysis of Gag indicated that the matrix domain (MA) is required
for Vpu responsiveness. However, additional mutations in other domains of Gag, which affect the formation of stable virus
particles, also abrogate Vpu responsiveness on total Gag release. Coexpression of the wild-type gag gene and a gag mutant
lacking the MA domain renders the MA0 mutant Vpu responsive. This indicates that Gag molecules lacking MA are still
incorporated into particles through association with wild-type Gag molecules and that the resulting composite particles are
sufficient for Vpu-mediated exit. q 1997 Academic Press
INTRODUCTION 1993; Schubert et al., 1992; Strebel et al., 1989). Vpu
has two distinctive biological activities. First, the protein
Human immunodeficiency virus type-1 (HIV-1) is a hu- enhances virus particle release from the cell surface (Fri-
man lentivirus. As with most retroviruses, including the borg et al., 1994; Geraghty and Panganiban, 1993; Klim-
type-C retroviruses, the assembly of lentiviruses appears kait et al., 1990; Schubert and Strebel, 1994; Schubert et
to occur at the plasma membrane (Chatterjee et al., 1992; al., 1995; Yao et al., 1992) through an unknown mecha-
Gelderblom et al., 1987). The paradigm of capsid forma- nism. Second, Vpu induces CD4 degradation in the endo-
tion is that Gag molecules associate with the plasma plasmic reticulum (Bour et al., 1995; Buonocore et al.,
membrane by virtue of the matrix domain (MA) of the 1994; Chen et al., 1993; Friborg et al., 1994; Geleziunas
Gag precursor (Spearman et al., 1994; Weaver and Pan- et al., 1994; Kimura et al., 1994; Lenburg and Landau,
ganiban, 1990; Zhou et al., 1994). The N-terminus of MA 1993; Raja et al., 1994; Schubert and Strebel, 1994; Vin-
is composed of adjacent hydrophobic amino acids and cent et al., 1993; Willey et al., 1994, 1992a,b; Yao et al.,
becomes myristoylated in the cytoplasm (Gelderblom, 1995). Vpu itself has not been found in virus particles,
1991; Wills and Craven, 1991). Intermolecular interaction and the ability of Vpu to enhance particle release is inde-
of multiple aligned Gag molecules then results in the pendent of the Env-gp protein (Geraghty and Pangani-
formation of an immature (unprocessed) capsid. It ap- ban, 1993; Yao et al., 1992).
pears that specific association between MA and the viral Vpu has two structurally separable domains, and in a
envelope glycoprotein (Env-gp) facilitates the efficient up- general way, the two biological activities of Vpu can be
take of Env-gp into the viral envelope (Dorfman et al., attributed to each domain (Schubert et al., 1996). The N-
1994; Freed and Martin, 1995, 1996; Yu et al., 1992). How- terminal transmembrane domain of Vpu is important for
ever, particle release does not require Env-gp. Although anchoring the peptide to membranes and this segment
there is evidence that some processing can take place of Vpu is also responsible for facilitating virus particle
prior to particle release, processing is not required for release at the cell surface (Schubert et al., 1996). The
particle exit from cells (Kaplan and Swanstrom, 1991). cytoplasmic domain of Vpu is composed of two a-heli-
As with all replication-competent retroviruses, the HIV- ces, is phosphorylated (Henklein et al., 1993; Schubert
1 genome contains gag, pol, and env genes. HIV-1 also et al., 1994; Wray et al., 1995), and plays a crucial role
harbors six accessory genes designated vif, vpr, vpu, tat, in the degradation of CD4 (Bour et al., 1995; Chen et al.,
rev, and nef (Haseltine, 1991). Although these accessory 1993). CD4 degradation is mediated through interaction
genes are common to other lentiviruses such as SIV and between the C-terminus of Vpu and the cytoplasmic do-
HIV-2, the vpu gene is unique to HIV-1. Vpu is a 81- main of CD4, and is dependent on phosphorylation of
amino-acid oligomeric integral membrane phosphopro- Vpu (Bour et al., 1995; Buonocore et al., 1994; Chen et
tein (Friborg et al., 1995; Jabbar, 1995; Maldarelli et al., al., 1993; Schubert and Strebel, 1994).
In considering the mechanism by which Vpu enhances
particle release, it is reasonable to hypothesize that Vpu1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (608) 262-2824. E-mail: Panganiban@oncology.wisc.edu. enhances virus particle release through interaction with
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a target or targets on virus particles. Therefore, proteins was created by introducing a BssHII–SpeI fragment of
pDMAXba into pHJ121. pDMAXba was digested withincorporated in the virions could be considered candi-
date targets for Vpu. In addition to Gag and Env-gp pro- XbaI and SpeI, and the compatible ends of XbaI and SpeI
were ligated to create pDMACAXba-Spe. The SalI–NheIteins, HIV-1 particles also contain the pol gene products
including protease, integrase, and reverse transcriptase. fragment from pHJ121 containing a Vpu mutation was
introduced into pDMACAXba-Spe to create pDMA-In addition, Vpr (Checroune et al., 1995; Cohen et al.,
1990; Kondo et al., 1995; Lavallee et al., 1994; Lu et al., CAXba-SpeVpu0. pDCANsi-Pst was created by cleavage
of pMS156 with NsiI and PstI and ligation of the compati-1993; Yuan et al., 1990), Vif (Karczewski and Strebel,
1996), and a cellular protein, cyclophilin A (Franke et al., ble ends similarly to the method previously described
(Wang and Barklis, 1993). pDCANsi-PstVpu0 was cre-1994; Thali et al., 1994) have been identified in the virion.
In this study we describe experiments to identify the ated by introducing a BssHII–SpeI fragment of pDCANsi-
Pst into pHJ121. pDNCApa was created by digestingtarget and requirements for Vpu-mediated particle re-
lease. We find that the Gag precursor protein is sufficient pMS156 with ApaI, then the 3* single-stranded exten-
sions were removed using the exonuclease activity of T4as a target for Vpu and that the MA domain is required
for Vpu responsiveness during particle release. DNA polymerase and ligated in a manner similar to that
previously described (Spearman et al., 1994). DNCApa
mutation results in a frame shift at codon 407 of the GagMATERIALS AND METHODS
open reading frame and a termination codon 16 codons
DNA constructs and mutagenesis
downstream (Spearman et al., 1994). The SalI–NheI
fragment from pHJ121 containing a Vpu mutation wasA ‘‘constitutive transport element’’ (CTE) DNA frag-
ment derived from Mason – Pfizer monkey virus (Bray et introduced into pDNCApa to create pDNCApaVpu0.
pDNC1922Xba was created by PCR mutagenesis fromal., 1994) was amplified by PCR and cloned into pBlue-
script SK (0) (Strategene, La Jolla, CA) between the pMS156 using two mutagenesis primers: 1922Xba
sense, 5*-ACCATAATGATCTAGAAAGGCAAT-3* (XbaI)BamHI and the PstI site in the polylinker region to pro-
duce pBS-SK-CTE. The U3 portion of the HIV-1 5* long and 1922Xba antisense, 5*-ATTGCCTTTCTAGATCAT-
TATGGT-3* (XbaI). In pDNC19922Xba, a premature stopterminal repeat DNA sequence from RNA sequence nu-
cleotide /1 in pMSMBA (McBride and Panganiban, codon was introduced to delete entire nucleocapsid (NC)
and p6 regions of the Gag sequence, and a novel1996) was replaced with the CMV promoter to create
pCMV(/1)MSMBA. A SpeI – BclI fragment of pMS156, XbaI site was introduced at the site of the stop codon.
pDNC1922XbaVpu0 was created by introducing thecontaining a premature stop codon in the pol open read-
ing frame, was introduced into pCMV(/1)MSMBA to SpeI–ApaI fragment of pDNC1922Xba into pHJ121. Fi-
nally, pD1469Xba mutant was created by PCR mutagene-create pCMV(/1)MSMBApol0. pCMV(/1)MSMBApol0
was then digested with BclI and XhoI and a BamHI – sis using two mutagenesis primers: 1469 sense, 5*-GCA-
CCAGGCCTCTAGAGAGAACCA-3* (XbaI) and 1469 anti-XhoI fragment from pBS-SK-CTE containing the CTE
was inserted to create pGagCTE. The DNA sequence sense, 5*-TGGTTCTCTCTAGAGGCCTGGTGC-3* (XbaI).
pD1469XbaVpu0 was created by introducing a BssHII –between the major splice donor (around nucleotide 743)
and splice acceptor 5 (around nucleotide 6045) of SpeI fragment of pD1469Xba into pHJ121.
HIV-1 (Schwartz et al., 1990) was precisely deleted by
PCR mutagenesis from pCMV(/1)MSMBA to create Cell culture, sample preparation, and Western blot
pCMVVpu. The pCMVVpu was digested with NheI and analysis
XhoI and a XbaI – XhoI fragment from pBS-SK-CTE was
inserted by ligation to produce pVpuCTE. HeLa cells were maintained in Dulbecco’s modified
Eagle’s medium with high glucose (DMEM) supple-All the HIV-1 Gag deletion constructs were derived
from pMS156, which has a premature stop codon muta- mented with 7% calf serum. One day before transfection,
0.8 million cells were seeded onto each 100-mm dish.tion in the pol open reading frame at nucleotide 2259.
pHJ121 was created by introducing a SalI–NheI fragment Calcium phosphate coprecipitation followed by glycerol
shock was used for DNA transfection. Forty-eight to sixtyfrom pMS173 (Schwartz et al., 1996), which has a trun-
cated form of Vpu, into pMS156. As a consequence, hours after transfection, cells were washed twice with
phosphate-buffered saline (PBS) and then 2 ml DMEMpHJ121 is a protease-minus and Vpu-minus derivative
of HIV-1 strain NL4-3. pDMAXba was created by PCR was added to each 100-mm plate. After 90 min of incuba-
tion at 377, the medium was collected and subjectedmutagenesis from pMS156 using two mutagenesis prim-
ers: DMAXba sense, 5*-TTAGATAAATCTAGAGACACA- to low-speed centrifugation to remove cell debris. The
supernatant was transferred to a Centricon-30 or Centri-GGA-3* (XbaI) and DMAXba antisense, 5*-TCCTGTGTC-
TCTAGATTTATCTAA-3* (XbaI). In pDMAXba, the DNA con-10 (Amicon, MA) and then concentrated to a 35-ml
final volume. The Centicon filters allow all Gag proteinssequence from nucleotide 835 to 1149 was deleted
and a novel XbaI site was introduced. pDMAXbaVpu0 released in the 1.5-hr period to be collected and concen-
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trated. Alternatively, virus particles were prepared by al., 1993). To express Vpu, the Vpu open reading frame
was introduced at a position distal to the CMV promotersedimentation through sucrose cushions. In this case,
virus was pelleted by ultracentrifugation through a 5-ml to create pVpuCTE (Fig. 1A). HeLa cells were transfected
with the pGagCTE along with pVpuCTE or with a control20% sucrose cushion (Beckman SW28 rotor at 25,000
rpm for 2 hr) after being subjected to low-speed centrifu- plasmid that does not express Vpu, and 2 days post-
transfection the cells were washed and fresh mediumgation to remove cell debris. Virus pellets were resus-
pended in a resuspension buffer (0.5% sodium deoxycho- was added. After 90 min the medium was collected and
centrifuged to remove cell debris and then concentratedlate, 0.1% SDS, 1% Triton X-100, 20 mM Tris, 150 mM
NaCl, 1 mM EDTA, 0.02% NaN3 , pH 7.5). To obtain cyto- as described under Materials and Methods. Collected
media, pelleted viruses, and cell lysates were subjectedplasmic fractions for analysis of intracellular protein,
cells were rinsed with PBS, lysed with 150 ml Triton lysis to SDS–PAGE followed by Western blot analysis using a
rabbit anti-Gag antibody and visualized with a 35S-labeledbuffer (0.5% Triton X-100, 50 mM Tris, 300 mM NaCl, pH
7.5), and incubated on ice for 30 min. Nuclei were pel- goat anti-rabbit IgG antibody. As shown in Fig. 1B, extra-
cellular release of the Gag precursor was significantlyleted at 7000 rpm using a microcentrifuge for 6 min and
the supernatant was recovered. For Western analysis, enhanced when cotransfected with the pVpuCTE (lane
1) compared to the control vector DNA (lane 2), while41 protein sample buffer (8% SDS, 50 mM Tris, 40%
glycerol, 24.8 mg/ml DTT, 0.4% bromophenol blue, 5% 2- intracellular Gag expression levels were similar in the
presence or absence of Vpu (lane 4 and lane 5). Pelletedmercaptoethanol, pH 6.8) was added to the collected
media and cell lysate samples. Samples were placed in virus particles were also enhanced in the presence of
Vpu. After calculation using a calibration curve (data nota boiling water bath for 4 min and then subjected to
SDS–PAGE followed by Western blot analysis. A poly- shown), we estimate that Vpu enhanced total Gag re-
lease by about fivefold and the enhancement effect onclonal rabbit anti-Gag antibody was used as the primary
antibody. A 35S-labeled goat anti-rabbit IgG antibody (Am- pelleted viruses was larger than fivefold. This is consis-
tent with observations from previous reports (Schubertersham, Arlington Heights, IL) was used as the second-
ary antibody. Phosphorimage analysis was used for and Strebel, 1994; Schubert et al., 1995), although a much
larger effect of Vpu on particle release has also beenquantitative measurement of Western blots. The entire
sample from collected media (approximate final volume reported (Gottlinger et al., 1993). Therefore, we conclude
that Gag precursor protein itself is sufficient to generate50 ml) or 40 ml of cell lysate was loaded into each well
of an SDS–PAGE gel. Calibration curves were generated a target for Vpu’s enhancement effect. Our result is also
consistent with a previous report (Schubert and Strebel,by loading various amounts of Gag antigen into an SDS –
PAGE gel for Western blot analysis. Extracellular Gag 1994) that Vpu does not enhance the release of free Gag
proteins.release efficiency was determined using the ratio of ex-
tracellular Gag signal over intracellular Gag signal. Rela-
tive Gag release efficiency for each mutant was calcu- The matrix domain of Gag is required for Vpu
lated by using the extracellular release efficiency of the responsiveness
wild-type Gag (Vpu/) as 100%.
To identify which region in Gag precursor is responsi-
ble for Vpu’s target, we created several Gag deletion orRESULTS
truncation mutants as depicted in Fig. 2. As with pGag-
HIV-1 Gag precursor is sufficient as a target for Vpu
CTE, these mutants are protease minus and the Gag
precursor would not be expected to be proteolyticallyHIV-1 Gag protein is sufficient for virus capsid forma-
tion (Rasmussen et al., 1990). To determine whether Gag processed. Mutant DMACAXba-Spe has a deletion in
the Gag coding region from nucleotide 835 to 1512 (cor-is also enough to provide a target for Vpu-mediated parti-
cle release, we expressed Gag from an expression con- responding to NL4-3 DNA coordinates) extending from
MA into the capsid domain (CA), and DMAXba containsstruct lacking the other viral genes and measured parti-
cle release in the presence or absence of concurrent a deletion in the coding region from nucleotide 835 to
1149 in the MA region. In both mutants the myristoylationVpu expression. In pGagCTE the gag gene was ex-
pressed from the CMV promoter as shown in Fig. 1A. signal was left intact since the signal is crucial for virus
particle formation (Gottlinger et al., 1989). MutantThe CTE from Mason–Pfizer monkey virus is a cis-acting
sequence that facilitates exit of RNA from the nucleus DCANsi-Pst contains a deletion from nucleotide se-
quence 1252 to 1419 in the CA region. Although CA may(Bray et al., 1994). Thus, the CTE was included in pGag-
CTE in order to express proteins efficiently. Gag ex- contain determinants important for Gag–Gag associa-
tion and resultant capsid formation, loss of this segmentpressed from pGagCTE would be expected to be in pre-
cursor form since the viral protease is not expressed. of CA may not be absolutely crucial for particle formation
(Wang and Barklis, 1993). Mutant DNCApa contains aThis does not affect Vpu responsiveness since Vpu facili-
tates the release of unprocessed particles (Gottlinger et premature stop codon to delete the Gag sequence fol-
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FIG. 1. The HIV-1 Gag precursor is a target for Vpu. (A) Diagram of pGagCTE and pVpuCTE DNA constructs. (B) Export of Gag protein following
transfection with pGagCTE. HeLa cells were transfected with pGagCTE and intracellular and extracellular Gag was detected and quantified as
described in the text and under Materials and Methods. In addition to p55 Gag, the positions of relevent size markers are indicated. (C) The
efficiency of Gag release in the presence and absence of Vpu. Extracellular Gag release efficiency was determined using the ratio of extracellular
Gag over intracellular Gag as determined by phosphorimager analysis. The Gag release efficiency in the presence of Vpu is normalized to 100%.
lowing the first zinc finger motif in the NC region, and and p6 domains using a premature stop codon and an
XbaI site at nucleotide 1922, and the D1469Xba mutantthis mutant has also been shown previously to form virus
particles successfully (Spearman et al., 1994). Finally, the contains the entire MA region plus a small segment of
the adjoining CA region.DNC1922Xba deletes Gag sequence of the entire NC
FIG. 2. Gag deletion and truncation mutations. The nature of the mutations is described in the text. The putative zinc-finger motifs are shown as
solid boxes in the NC region. A summary of the general phenotypes of these mutants, based on the data from Fig. 3, is also provided.
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FIG. 3. Vpu responsiveness of Gag mutants. DNA for each mutant was transfected into HeLa cells. Collected media (A), cell lysate samples (B),
and pelleted virus particles (C) from Gag mutants. Gag proteins were detected by Western blot analysis as described under Materials and Methods.
To determine whether deletion of these various re- DMACAXba-Spe, DMAXba, DNC1922Xba, and
D1469Xba were not measurably enhanced by the pres-gions of Gag had an effect on Gag release, each expres-
sion construct was transfected into HeLa cells in the ence of Vpu (lane 4 to lane 7 and lane 12 to lane 15 in
Fig. 3A), while expression levels of intracellular proteinspresence or absence of Vpu. Cell-free and intracellular
Gag protein was then collected and analyzed by Western were similar (corresponding lanes in Fig. 3B). In contrast,
extracellular Gag protein expressed from the DCANsi-blot analysis. Significant extracellular release of all Gag
proteins was detected as shown in Fig. 3A. However, Pst and DNCApa as well as from wild-type Gag could
be significantly enhanced by Vpu (lane 8 to lane 11 forextracellular releases of Gag derivatives from mutants
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FIG. 3—Continued
mutants and lane 2 to lane 3 for wild type). As shown in Our previous data derived from analysis of DMAXba
was consistent with the formation of particles from thisFig. 3C, DMACAXba-Spe, DNC1922Xba, and D1469Xba
were unable to form stable virus particles to be collected mutant, but the absence of the MA domain resulted in
the loss of Vpu responsiveness. Thus, we decided toby a sucrose cushion. On the other hand, the DMAXba
mutant was able to form stable virus particles but was coexpress Gag from DMAXba along with wild-type Gag
to determine whether DMAXba Gag might dominantlynot responsive to Vpu. Finally, DCANsi-Pst and DNCApa
were able to form stable virus particles and remained interfere with the Vpu responsiveness of wild-type Gag.
An alternative possibility would be that DMAXba GagVpu responsive (Fig. 3C). The results of Fig. 3 are also
summarized in Fig. 2. might be incorporated into composite mutant–wild-type
particles rendering DMAXba Gag Vpu responsive. Mu-The observation that DMACAXba-Spe and DMAXba
were unresponsive to Vpu is consistent with the idea tants DNC1922Xba and D1469Xba, which contain the
MA region, appeared to be incapable of forming parti-that the MA domain of Gag is required as a target for
Vpu. Similarly, lack of Vpu responsiveness in the absence cles. We similarly coexpressed these mutants with wild-
type Gag to see whether they would affect the releaseof all of NC and p6 (DNC1922Xba) suggests that the C-
terminal end of Gag is also required. However, unlike of wild-type particles. pDMAXba, pDNC1922Xba, and
pD1469Xba were cotransfected in parallel into HeLaother mutants (DCANsi-Pst and DNCApa, for example),
DNC1922Xba may not be able to form stable particles cells with either pMS156 (wild-type Gag, Vpu/) or pHJ121
(wild-type Gag, Vpu0). Interestingly, extracellular releasedue to a large deletion (Gheysen et al., 1989). Due to its
inability to form stable virus particles, we are not sure if of DMAXba Gag protein became Vpu responsive when
coexpressed with wild-type Gag (lane 2 and 3, Fig. 4).the NC domain is important for Vpu-mediated particle
release. Results from DNC1922Xba and D1469Xba sug- On the other hand, release of DNC1922Xba and
D1469Xba Gag remained unresponsive to Vpu (lane 4gest that the MA region is not sufficient for Vpu’s action.
In experiments with DMACAXba-Spe, we often noticed to lane 7, Fig. 4). None of the tested mutants negatively
interfered with extracellular release of the wild-type Gag.the formation of a Gag-derived peptide smaller that the
primary Gag produce in collected media (Fig. 3A, lanes The observation that the MA deletion mutant (DMAXba)
is able to form particles by itself, and also becomes Vpu4 and 5). We are unsure of the source of this Gag species
but speculate that this is a stable degradation product responsive in association with wild-type Gag molecules,
supports the idea that MA region is crucial for Vpu’sof the primary Gag product. The results of Fig. 3 suggest
the MA domain of HIV-1 Gag is required but not sufficient action. In addition, it appears that for Vpu-facilitated parti-
cle release the MA region need not be present on everyas a target for Vpu.
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FIG. 4. Coexpression of Vpu-unresponsive mutants with wild-type Gag. The mutant constructs were cotransfected with wild-type constructs
(MS156 for Vpu/, HJ121 for Vpu0) into HeLa cells individually. Collected media (A) and cell lysates (B) were prepared and analyzed by Western
blot analysis in the same manner as described in Fig. 3.
Gag molecule in the virus particle since composite parti- Although all Gag deletion mutant proteins could be
cles composed of Gag from DMAXba and wild type were detected in concentrated media (Fig. 3A), some of the
Vpu responsive. mutants could not form stable virus particles (Fig. 3C).
Extracellular release of Gag mutants which could not
DISCUSSION form stable virus particles were Vpu unresponsive re-
gardless of whether or not they contained the HIV-1 MAOur results demonstrate that HIV-1 Gag precursor pro-
region. Although the DNCApa was able to form virustein is sufficient as a target for Vpu during particle release
particles and was Vpu responsive, the DNC1922Xba mu-and that MA is an essential component of that target but
tant did not form stable virus particles and we cannotnot sufficient for Vpu’s ability to enhance extracellular
rule out a possible function of NC domain for Vpu-medi-release of Gag protein. DMAXba, a mutant devoid of
ated effect.much of the MA region, was especially informative. When
It should be noted that proteolytic processing of Gagexpressed alone, MA0 Gag protein from this mutant was
is not required for Vpu’s ability to enhance virus particleassembled into particles yet those particles were unre-
release. We examined protease-minus mutants to sim-sponsive to Vpu. However, mutant Gag molecules be-
plify the comparison of particle release for the variouscame Vpu responsive when wild-type Gag was simulta-
mutants, since some of the Gag mutations would beneously expressed. This complementation and rescue of
likely to affect cis-acting cleavage sites for protease. Sim-MA0 Gag indicates that the requirement of MA can be
ilarly, some Gag mutations might have been expected tocompensated in trans resulting in concomitant restora-
affect translational frame-shifting efficiency into the poltion of Vpu responsiveness. To try to understand the
gene (data not shown). Such extraneous effects werespecificity between Vpu and Gag, we replaced the HIV-
obviated simply by using PR0 derivatives.1 MA region with the MA region of spleen necrosis virus
The mechanism of Vpu action could be mediated(SNV) Gag. However, we were unable to determine
through either direct or indirect interaction between Vpuwhether the SNV MA was involved in Vpu-mediated parti-
and Gag. It is intriguing that the MA of Gag (Zhou et al.,cle release since this chimeric Gag did not form stable
1994) and Vpu are both membrane associated. Severalvirus particles as examined using ultracentrifugation
mutants with single amino acid substitutions or smallthrough sucrose cushion (data not shown). Thus, it re-
deletions in the MA region have been shown to dramati-mains unclear whether HIV-1 MA is specifically required
for Vpu responsiveness. cally reduce the efficiency of virus particle production
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of heterologous protein degradation by the Vpu protein of HIV-1(Freed et al., 1994; Yu et al., 1992; Yuan et al., 1993) or
requires the transmembrane and cytoplasmic domains of CD4. Virol-other steps in virus life cycle (Casella et al., 1997). If
ogy 204, 482–486.
interaction between MA and Vpu is direct, Vpu might Callahan, M. A., Handley, M. A., Talbot, K. J., Lee, Y.-H., Harper, J. W.,
interact with a region of MA affected by these mutations. and Panganiban, A. T. A novel member of the tetratricopeptide repeat
protein family functionally interacts with human immunodeficiencyHowever, to date, there is no evidence for direct interac-
virus-type 1 Vpu and Gag proteins. [In preparation]tion between Gag and Vpu. On the other hand, if there
Casella, C. R., Raffini, L. J., and Panganiban, A. T. (1997). Pleiotropicis indirect interaction between Vpu and Gag, that interac-
mutations in the HIV-1 matrix protein that affect diverse steps in
tion would have to be mediated through cellular factors replication. Virology 228, 294–306.
since our results have ruled out the involvement of other Chatterjee, S., Basak, S., and Khan, N. C. (1992). Morphogenesis of
human immunodeficiency virus type 1. Pathobiology 60, 181–186.viral gene products as Vpu targets. If the interaction be-
[Review]tween Vpu and Gag is indirect, in a general sense, cellu-
Checroune, F., Yao, X. J., Gottlinger, H. G., Bergeron, D., and Cohen,lar proteins that bind to either protein are candidates for
E. A. (1995). Incorporation of Vpr into human immunodeficiency virus
intermediaries. Cyclophilin A is incorporated into HIV-1 type 1: Role of conserved regions within the P6 domain of Pr55gag.
virus particles through interaction with a proline-rich re- J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 10, 1–7.
Chen, M. Y., Maldarelli, F., Karczewski, M. K., Willey, R. L., and Strebel,gion in the CA and this region is not conserved in the
K. (1993). Human immunodeficiency virus type 1 Vpu protein inducesclosely related SIV Gag (Franke et al., 1994). However,
degradation of CD4 in vitro: The cytoplasmic domain of CD4 contri-SIV Gag is Vpu responsive (data not shown) and a previ-
butes to Vpu sensitivity. J. Virol. 67, 3877–3884.
ous report demonstrated that Vpu facilitates the release Cohen, E. A., Dehni, G., Sodroski, J. G., and Haseltine, W. A. (1990).
of Gag proteins of HIV-2, visna virus, and Moloney murine Human immunodeficiency virus vpr product is a virion-associated
regulatory protein. J. Virol. 64, 3097–3099.leukemia virus (Gottlinger et al., 1993). Thus, it is not
Dorfman, T., Mammano, F., Haseltine, W. A., and Gottlinger, H. G.likely that cyclophilin A serves as an intermediary be-
(1994). Role of the matrix protein in the virion association of thetween Vpu and MA interaction. Furthermore, cyclophilin
human immunodeficiency virus type 1 envelope glycoprotein. J. Virol.
B (Franke et al., 1994; Luban et al., 1993) and cyclophilin 68, 1689–1696.
C (Franke et al., 1994), which interact with Gag protein Franke, E. K., Yuan, H. E. H., and Luban, J. (1994). Specific incorporation
of cyclophilin A into HIV-1 virions. Nature 372, 359–362.in vitro, and a Vpu-binding protein (UBP), which interacts
Freed, E. O., and Martin, M. A. (1995). Virion incorporation of envelopewith Vpu (Callahan et al., in preparation; Geraghty et al.,
glycoproteins with long but not short cytoplasmic tails is blocked by1994), can be considered candidates for intermediaries
specific, single amino acid substitutions in the human immunodefi-
between Vpu and Gag. Finally, it has been shown re- ciency virus type 1 matrix. J. Virol. 69, 1984–1989.
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